UBS has released a research report stating that China Life Insurance Company Limited (SEHK: 02628) expects agent first-year regular premiums (FYRP) to record positive growth during the "good start" period, with high-dividend stock allocation in line with targets. The report maintains a "Buy" rating on the H-shares with a target price of HK$36.
UBS noted that China Life Insurance Company Limited (SEHK: 02628) expects agent FYRP to achieve positive growth during the "good start" period, supported by a recovery in agent headcount and quality improvement. China Life Insurance Company Limited believes that the bancassurance channel continues to be dragged by Document No. 65 (fee management); although bancassurance FYRP rebounded month-on-month from July to September, September remained below the monthly average of the first half, indicating that the impact of Document No. 65 is still ongoing. The company noted that bancassurance accounts for approximately 40% of the industry's FYRP in the first quarter of 2026. For 2027, double-digit agent new business value growth is an ambitious target, while bancassurance growth is expected to slow compared to the previous year.
The bank pointed out that the company's 2026 target for operating profit after tax (OPAT) is double-digit growth. Third-quarter OPAT rose 21% year-on-year (compared to a 13% increase in the first half), mainly driven by increased dividend income. OPAT is not an indicator within the Ministry of Finance's assessment framework, and dividends are currently not linked to OPAT, but the bank believes OPAT will become increasingly important for dividend decisions. The company is committed to providing stable per-share dividend growth over the long term.
UBS further noted that the company's equity exposure has reached 18% to 19%, approaching its strategic asset allocation target. In the first nine months of this year, the company increased its holdings of approximately RMB 200 billion in fair value through other comprehensive income (FVOCI) stocks, while reducing approximately RMB 100 billion in growth-oriented shares. Currently, high-dividend stock allocation is in line with targets, and if risk-reward becomes more attractive, the company is willing to further increase FVOCI exposure to enhance earnings stability. The yield on new funds is 2.2%, well above the new policy break-even yield of 1.2%. Solvency sensitivity to stock price risk is limited, with interest rates being a more sensitive factor; if interest rates remain at current levels, the solvency ratio in the fourth quarter is expected to be broadly stable quarter-on-quarter. The upcoming implementation of Solvency II Phase III is expected to significantly improve the company's solvency.
Comments